Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBM076 in stable COPD with small airway disease
NL-OMON41772Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of qbm-076 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoints: Lung clearance index, Absolute number of sputum neutrophils and 2 more. Started May 2015; status: active, not recruiting.
02
Drugs
qbm-076
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41772.